A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer
A Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HDM2017 Combination Therapy in Participants With Advanced Colorectal Cancer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
220 participants
Aug 18, 2026
INTERVENTIONAL
Conditions
Summary
This is a multicenter, open-label, dose-escalation/dose-expansion, Phase Ib/II study to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor efficacy of HDM2017 combination therapy in participants with advanced CRC. The study is divided into two periods: dose escalation (Phase Ib) and dose expansion (Phase II). Phase Ib of this study is a dose-finding study of different HDM2017 combination therapies. The Phase II study will be conducted at a dose determined to be safe and potentially effective in Phase Ib.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administered with continuing until protocol-specified criteria for treatment discontinuation are met
administered with continuing until protocol-specified criteria for treatment discontinuation are met
administered with continuing until protocol-specified criteria for treatment discontinuation are met
administered with continuing until protocol-specified criteria for treatment discontinuation are met
administered with continuing until protocol-specified criteria for treatment discontinuation are met
administered with dosing continuing until protocol-specified criteria for treatment discontinuation are met
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07805551